Literature DB >> 27210465

Malignancy in dermatomyositis and polymyositis: analysis of 192 patients.

Yao-Fan Fang1, Yeong-Jian Jan Wu1,2, Chang-Fu Kuo1, Shue-Fen Luo1, Kuang-Hui Yu3.   

Abstract

This study aims to investigate the prevalence and predictive risk factors of malignancy in patients with polymyositis (PM) and dermatomyositis (DM). The medical records of 192 PM/DM patients followed up in a medical center between January 2000 and December 2013 were reviewed. Among the 192 patients, 33 patients (17.2 %) had associated cancer. Both PM and DM are significantly associated with cancer, although the risk of cancer appears to be somewhat higher among patients with DM (23.0 %) than among those with PM (8.9 %). Nasopharyngeal cancer (30.3 %) and breast cancer (18.2 %) comprised the most common malignant diseases associated with PM/DM. Univariate analysis showed that an older age at PM/DM onset, heliotrope rash, Gottron's sign, dysphagia, and low creatine phosphokinase (CPK) level were associated with increased malignancy. Multivariate analysis revealed that independent predictors of malignancy in PM/DM were age >40 years at PM/DM onset (adjusted OR 3.44; 95 % CI 1.08-10.98; p = 0.037) and heliotrope rash (adjusted OR 2.96; 95 % CI 1.04-8.43; p = 0.042). During the follow-up period, 66 (34.4 %) patients died and the overall patient survival rates were 83.1 % at 1 year, 78.9 % at 2 years, 74.2 % at 5 years, and 65.5 % at 10 years. This study demonstrates a high frequency of malignancy (17.2 %) in DM/PM patients. Nasopharyngeal cancer and breast cancer were the most common cancer types in DM/PM patients in our study. Cancer screening should be offered to patients with newly diagnosed DM/PM. Moreover, all patients should be evaluated for the possibility of an underlying malignancy during treatment.

Entities:  

Keywords:  Age; Dermatomyositis; Malignancy; Polymyositis; Risk factors

Mesh:

Year:  2016        PMID: 27210465     DOI: 10.1007/s10067-016-3296-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  53 in total

1.  Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy.

Authors:  R E Hunger; C Dürr; C U Brand
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

2.  Survival, mortality and causes of death in inflammatory myopathies.

Authors:  Carmen Torres; Rebeca Belmonte; Loreto Carmona; F Javier Gómez-Reino; María Galindo; Belén Ramos; Ana Cabello; Patricia E Carreira
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

3.  Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study.

Authors:  C-F Kuo; L-C See; K-H Yu; I-J Chou; H-C Chang; M-J Chiou; S-F Luo
Journal:  Br J Dermatol       Date:  2011-11-03       Impact factor: 9.302

4.  Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis.

Authors:  Laurence Fardet; Alain Dupuy; Murielle Gain; Adrien Kettaneh; Patrick Chérin; Hervé Bachelez; Louis Dubertret; Celeste Lebbe; Patrice Morel; Michel Rybojad
Journal:  Medicine (Baltimore)       Date:  2009-03       Impact factor: 1.889

5.  Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy.

Authors:  N H Cox; C M Lawrence; J A Langtry; F A Ive
Journal:  Arch Dermatol       Date:  1990-01

6.  Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

Authors:  W H Chow; G Gridley; L Mellemkjaer; J K McLaughlin; J H Olsen; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

7.  Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients.

Authors:  Agnès Sparsa; Eric Liozon; François Herrmann; Kim Ly; Valérie Lebrun; Pascale Soria; Véronique Loustaud-Ratti; Marie-Laure Bouyssou-Gauthier; Serge Boulinguez; Christophe Bédane; Marie-Odile Jauberteau; Elisabeth Vidal; Jean-Marie Bonnetblanc
Journal:  Arch Dermatol       Date:  2002-07

Review 8.  Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis.

Authors:  J P Callen
Journal:  Rheum Dis Clin North Am       Date:  1994-11       Impact factor: 2.670

9.  Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA.

Authors:  Brendan B Antiochos; Lin A Brown; Zhongze Li; Tor D Tosteson; Robert L Wortmann; William F C Rigby
Journal:  J Rheumatol       Date:  2009-11-16       Impact factor: 4.666

Review 10.  Malignancy and idiopathic inflammatory myopathies.

Authors:  Patompong Ungprasert; Narandra K Bethina; Christine H Jones
Journal:  N Am J Med Sci       Date:  2013-10
View more
  16 in total

1.  Breast cancer and dermatomyositis: a case study and literature review.

Authors:  E Hendren; O Vinik; H Faragalla; R Haq
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.

Authors:  Kyoko Motomura; Hiroyuki Yamashita; Saeko Yamada; Yuko Takahashi; Hiroshi Kaneko
Journal:  Rheumatol Int       Date:  2019-08-23       Impact factor: 2.631

3.  Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis.

Authors:  Zoltan Griger; Katalin Danko; Gabor Nemeth; Ziad Hassan; Zsuzsa Aszalos; Katalin Szabo; Levente Bodoki; Rudolf Gesztelyi; Judit Zsuga; Peter Szodoray; Adam Kemeny-Beke
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

4.  A Unique Case of Muscle-Invasive Metastatic Breast Cancer Mimicking Myositis.

Authors:  Janelle Gyorffy; Samuel M Philbrick; Adrian R Bersabe; Richard J Upton; Derek A Mathis; Austin Peters; Alexander Brown
Journal:  Case Rep Oncol Med       Date:  2017-06-28

5.  Dermatomyositis Associated with Lung Neuroendocrine Carcinoma.

Authors:  Reina Takashima; Kazufumi Takamatsu; Yutaka Shinkawa; Masato Yagita; Motonari Fukui; Masaaki Fujita
Journal:  Intern Med       Date:  2017-03-17       Impact factor: 1.271

6.  The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.

Authors:  Yumiko Sugiyama; Ryusuke Yoshimi; Maasa Tamura; Mitsuhiro Takeno; Yosuke Kunishita; Daiga Kishimoto; Yuji Yoshioka; Kouji Kobayashi; Kaoru Takase-Minegishi; Toshiyuki Watanabe; Naoki Hamada; Hideto Nagai; Naomi Tsuchida; Yutaro Soejima; Hiroto Nakano; Reikou Kamiyama; Takeaki Uehara; Yohei Kirino; Akiko Sekiguchi; Atsushi Ihata; Shigeru Ohno; Shouhei Nagaoka; Hideaki Nakajima
Journal:  Arthritis Res Ther       Date:  2018-01-11       Impact factor: 5.156

7.  A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Authors:  Alexander G S Oldroyd; Andrew B Allard; Jeffrey P Callen; Hector Chinoy; Lorinda Chung; David Fiorentino; Michael D George; Patrick Gordon; Kate Kolstad; Drew J B Kurtzman; Pedro M Machado; Neil J McHugh; Anna Postolova; Albert Selva-O'Callaghan; Jens Schmidt; Sarah Tansley; Ruth Ann Vleugels; Victoria P Werth; Rohit Aggarwal
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

8.  Occurrence of Dermatomyositis Immediately after Mastectomy Subsequent to Severe Chemotherapeutic Drug Eruption.

Authors:  Yuki Otsuka; Haruki Watanabe; Yuzuki Kano; Noriko Tatebe; Katsue Sunahori-Watanabe; Tomoko Kawabata; Ken-Ei Sada; Jun Wada
Journal:  Intern Med       Date:  2017-12-15       Impact factor: 1.271

9.  Endoscopy is of low yield in the identification of gastrointestinal neoplasia in patients with dermatomyositis: A cross-sectional study.

Authors:  Trilokesh D Kidambi; Gabriela Schmajuk; Andrew J Gross; James W Ostroff; Jonathan P Terdiman; Jeffrey K Lee
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742

10.  Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.

Authors:  Ying Liu; Lulu Xu; Hongliang Wu; Na Zhao; Yanchun Tang; Xiaoping Li; Ying Liang
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.